How has the advent of novel agents impacted the management of multiple myeloma? In this activity, blood oncology experts Jacob Laubach, MD, MPP; Constantine S. Mitsiades, MD, PhD; Kenneth C. Anderson, MD; and Paul Richardson, MD, team up to explore the impact novel agents have had on the evolution of combination treatment strategies for multiple myeloma, as well as patient outcomes.

Learn More/Begin Activity

This multi-component activity features a slide presentation from blood oncology expert Paul G. Richardson, MD, followed by a Q&A exchange between Dr. Richardson and medical oncologist Mecide M. Gharibo, MD. Topics addressed include recent advances in multiple myeloma (MM) treatment; the clinical rationale for targeted therapy, including accumulating data regarding the physiologic role of the bone marrow microenvironment in MM pathogenesis; and the evolution of a new treatment paradigm built on targeted therapy, novel treatments, and individualized care.

Learn More/Begin Activity

Blood oncology expert Peter M. Voorhees, MD, discusses the biologic effects of novel targeted therapies for multiple myeloma and their impact on patient outcomes. Topics covered include the interaction between multiple myeloma cells and the bone marrow microenvironment; the role of the ubiquitin-proteasome pathway; and the potential for drugs under development to target disease pathogenesis and further improve outcomes.

Learn More/Begin Activity

In this Q&A podcast activity, Paul G. Richardson, MD, is interviewed on the latest advances in multiple myeloma treatment, including immunomodulatory drugs that target the bone marrow microenvironment, optimal timing for stem cell harvesting, and promising agents currently under investigation.

Learn More/Begin Activity

In this Q&A podcast activity, blood oncology expert Mecide M. Gharibo, MD, reflects on how the advent of novel agents and treatment strategies has revolutionized the treatment of multiple myeloma. Dr. Gharibo specifically discusses the impact of new and emerging therapies, the value of combination treatment, and the importance of individualizing treatment in the management of multiple myeloma.

Learn More/Begin Activity

Blood oncology expert William Bensinger, MD, discusses the relevance of stem cell transplantation in the context of new drug combinations and emerging clinical trial data concerning the optimal management of multiple myeloma.

Learn More/Begin Activity

In this learning activity, blood oncology expert and NCCN Multiple Myeloma Panel member William Bensinger, MD, discusses topics such as individualized treatment strategies, emerging therapies, and the value of combination treatment in the management of multiple myeloma.

Learn More/Begin Activity